B43-PAP IMMUNOTOXIN COMBINED WITH STANDARD 4 DRUG INDUCTION FOR CD+ ALL

CCG 0957是一项I期研究，旨在确定B43-PAP的毒性， 同时给予标准的四种药物再诱导（阿托斯汀， 泼尼松、L '天冬酰胺酶、柔红霉素）治疗小儿急性 淋巴母细胞白血病（ALL）。 B43-PAP是一种免疫毒素（单克隆 抗体-毒素缀合物），其已经研究了9年 由Dr. Dr. Uckun在Children's Cancer Group免疫毒素资源 明尼阿波利斯的实验室。 单机构研究已经完成， 在明尼苏达大学。 B43是选择的单克隆抗体 因为它是针对CD 19抗原的， 对前B系ALL表现出特异性，前B系ALL是最常见的 儿童白血病

CCG 0957 is a phase-I study to determine the toxicity of B43-PAP when given concurrently with a standard four drug re-induction (Vincristine, Prednisone, L'Asparaginase, Daunomycin) in pediatric patients with acute lymphoblastic leukemia (ALL). B43-PAP is an immunotoxin (monoclonal antibody-toxin conjugate) which has been studied for the past 9 years by Dr. Fatih Uckun at the Children's Cancer Group Immunotoxin Resource Laboratory in Minneapolis. Single institution studies have been done at the University of Minnesota. B43 is the monoclonal antibody selected for the protocol because it is targeted toward the CD19 antigen, which displays specificity for pre-B lineage ALL - the most common type of leukemia in children.